Illumisoft's hospital program has no purchase orders and no funding. Parvis drops the deal its financing was raised for
Illumisoft is not a party to the hospital letters of intent behind its headline. Novra takes C$1.3 million from one trust that becomes an insider. Parvis ends its FavorPoint purchase and says money raised mainly for that deal went to Atlas One and working capital.
October 30, 2026 at 5:30 p.m. EDT · 2 min read

Illumisoft: a program, not an order
Illumisoft (TSXV: UVC) announced plans with CHAIR, a not-for-profit coalition, for a hospital research program on its SaniLume product: "13 linked studies" and "planned facility-wide installations" in Manitoba and British Columbia. The release's own disclosures are the story:
- The studies are "subject to funding, which has not yet been secured."
- The letters of intent are "non-binding," with health bodies in both provinces, and "Illumisoft is not a party to the letters of intent."
- The company "has not received any purchase orders in connection with the program," and "The number of units, pricing and other terms have not yet been finalized."
- "CHAIR does not receive any compensation from Illumisoft." Illumisoft "expects to enter into an agreement with CHAIR."
CHAIR intends to begin the studies in November 2026. Until there is funding and an order, this is a research plan with a public company's name attached.
Novra: one buyer, a new insider
Novra Technologies (TSXV: NVI) agreed to sell 10,000,000 shares at C$0.13 for C$1.3 million to a single subscriber, "The David E. Chymiak Trust dated December 15, 1999." After closing the trust would hold about 16.6% and "will become an Insider." No finder's fees apply. TSXV approval "has not yet been granted." Part of the money will "repay existing liabilities," alongside R&D and new markets. The release does not mention MI 61-101.
Parvis: the deal ends, the financing stays spent
Parvis Invest (TSXV: PVIS) terminated its purchase of FavorPoint Capital, a FINRA-registered broker-dealer, "by mutual written consent" on October 29. The TSXV "has not yet completed its review of the proposed transaction," and no termination fee is disclosed.
The concurrent financing announced May 28 and amended June 30 was "principally intended to fund the FavorPoint acquisition." Parvis "will not proceed with the remaining tranches," but the first tranche "remains outstanding in accordance with its terms," and its "proceeds have been applied to the Atlas One integration and working capital." Investors who funded a US expansion now hold paper financing a Canadian integration.
The numbers are small but improving. For the six months to September 30, revenue was C$1,386,510, up 21.0%, with net income of C$335,000 and normalized EBITDA of C$369,544 against negative C$88,906 a year earlier.
All figures and quotes are from the linked releases.
More from the Technology Desk
Pivotree calls a 20% revenue drop 'stabilizing' as its bank line is halved. Intermap's acquisition takes $7.7 million of a $12 million balance
Technology Desk · 10h ago

Pelican AI hires Machai for C$320,000 over three months as it lists in Frankfurt. Metatek's guidance needs its best quarter ever, by a wide margin
Technology Desk · 4d ago

WELL posts record revenue and a C$135.5 million loss, and its new guidance implies a smaller fourth quarter. VerticalScope signs two AI labs it will not name
Technology Desk · 7d ago
